Revised Guidance Document on Developing and Assessing Adverse Outcome Pathways
暂无分享,去创建一个
[1] M E Meek,et al. New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis , 2013, Journal of applied toxicology : JAT.
[2] Daniel L Villeneuve,et al. Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment , 2010, Environmental toxicology and chemistry.
[3] Igor Linkov,et al. Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence. , 2015, Regulatory toxicology and pharmacology : RTP.
[4] Jennifer Seed,et al. Overview: Using Mode of Action and Life Stage Information to Evaluate the Human Relevance of Animal Toxicity Data , 2005, Critical reviews in toxicology.
[5] B Alex Merrick,et al. Genomic and proteomic profiling for biomarkers and signature profiles of toxicity. , 2004, Current opinion in molecular therapeutics.
[6] M T D Cronin,et al. A review of the electrophilic reaction chemistry involved in covalent DNA binding , 2010, Critical reviews in toxicology.
[7] TG 442D. OECD GUIDELINE FOR THE TESTING OF CHEMICALS In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method , 2000 .
[8] Carolyn Vickers,et al. Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework. , 2011, Regulatory toxicology and pharmacology : RTP.
[9] D. Weed. Weight of Evidence: A Review of Concept and Methods , 2005, Risk analysis : an official publication of the Society for Risk Analysis.
[10] Leroy Hood,et al. The impact of systems approaches on biological problems in drug discovery , 2004, Nature Biotechnology.
[11] Jennifer Seed,et al. A Framework for Human Relevance Analysis of Information on Carcinogenic Modes of Action , 2003, Critical reviews in toxicology.
[12] Scott D. Kahn,et al. Current Status of Methods for Defining the Applicability Domain of (Quantitative) Structure-Activity Relationships , 2005, Alternatives to laboratory animals : ATLA.
[13] Carolyn Vickers,et al. IPCS framework for analysing the relevance of a cancer mode of action for humans , 2006 .
[14] Francesco Falciani,et al. Adverse Outcome Pathways for Regulatory Applications: Examination of Four Case Studies With Different Degrees of Completeness and Scientific Confidence. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.
[15] W Steiling,et al. Percutaneous penetration/dermal absorption of hair dyes in vitro. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.
[16] Nancy G Doerrer,et al. Identification and characterization of adverse effects in 21st century toxicology. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[17] Andrew Worth,et al. Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA). , 2014, Regulatory toxicology and pharmacology : RTP.
[18] A. B. Hill. The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.
[19] M Younes,et al. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. , 2001, Regulatory toxicology and pharmacology : RTP.
[20] R Jeffrey Lewis,et al. Mode of action human relevance (species concordance) framework: Evolution of the Bradford Hill considerations and comparative analysis of weight of evidence , 2014, Journal of applied toxicology : JAT.
[21] Alan R. Boobis,et al. IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans , 2008, Critical reviews in toxicology.
[22] Sharon Munn,et al. Adverse outcome pathway development II: best practices. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.
[23] Florian Nigsch,et al. Computational toxicology: an overview of the sources of data and of modelling methods. , 2009, Expert opinion on drug metabolism & toxicology.
[24] Hugh A Barton,et al. The Acquisition and Application of Absorption, Distribution, Metabolism, and Excretion (ADME) Data in Agricultural Chemical Safety Assessments , 2006, Critical reviews in toxicology.
[25] R. Kavlock,et al. Biological modeling of 5-fluorouracil developmental toxicity. , 1995, Toxicology.
[26] Nicole C. Kleinstreuer,et al. Disruption of embryonic vascular development in predictive toxicology. , 2011, Birth defects research. Part C, Embryo today : reviews.
[27] Steven K. Gibb. Toxicity testing in the 21st century: a vision and a strategy. , 2008, Reproductive toxicology.
[28] Melvin E. Andersen,et al. New directions in toxicity testing. , 2011, Annual review of public health.
[29] Stefan Scholz,et al. Adverse outcome pathways during early fish development: a conceptual framework for identification of chemical screening and prioritization strategies. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[30] Daniel L Villeneuve,et al. Vision & strategy: Predictive ecotoxicology in the 21st century , 2011, Environmental toxicology and chemistry.
[31] H J Clewell,et al. Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene. , 1995, Chemosphere.
[32] Cheryl A Murphy,et al. Adverse outcome pathways and ecological risk assessment: Bridging to population‐level effects , 2011, Environmental toxicology and chemistry.
[34] J. Haines,et al. International programme on chemical safety , 1996, The Lancet.
[35] Melvin E Andersen,et al. Defining and modeling known adverse outcome pathways: Domoic acid and neuronal signaling as a case study , 2011, Environmental toxicology and chemistry.
[36] John H. Duffus,et al. Appendix B: Glossary of Terms Used in Toxicology , 2006 .
[37] R. Huggett,et al. Biomarkers: Biochemical, Physiological, and Histological Markers of Anthropogenic Stress , 1992 .
[38] Dries Knapen,et al. The potential of AOP networks for reproductive and developmental toxicity assay development. , 2015, Reproductive toxicology.
[39] T. W. Schultz. Chapter 14:Adverse Outcome Pathways: A Way of Linking Chemical Structure to In Vivo Toxicological Hazards , 2010 .
[40] A. B. Hill,et al. "The Environment and Disease: Association or Causation?" (1965), by Austin Bradford Hill , 2017 .
[41] Stephen W. Edwards,et al. Reverse engineering adverse outcome pathways , 2011, Environmental toxicology and chemistry.
[42] Robert J Kavlock,et al. Computational toxicology--a state of the science mini review. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[43] Melvin E. Andersen,et al. The Future of Toxicity Testing , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.
[44] Sharon Munn,et al. Adverse outcome pathway (AOP) development I: strategies and principles. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.
[45] U. Epa. Guidelines for carcinogen risk assessment , 1986 .
[46] James R Wheeler,et al. Species extrapolation for the 21st century , 2011, Environmental toxicology and chemistry.
[47] Richard A Becker,et al. Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes. , 2015, Regulatory toxicology and pharmacology : RTP.
[48] Robert Landsiedel,et al. Intralaboratory validation of four in vitro assays for the prediction of the skin sensitizing potential of chemicals. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.